10/ 005,133

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Jun 03	New e-mail delivery for search results now available
NEWS 4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 7	Sep 03	JAPIO has been reloaded and enhanced
NEWS 8	Sep 16	Experimental properties added to the REGISTRY file
NEWS 9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11	Oct 24	BEILSTEIN adds new search fields
NEWS 12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13	Nov 18	DKILIT has been renamed APOLLIT
NEWS 14	Nov 25	More calculated properties added to REGISTRY
NEWS 15	Dec 04	CSA files on STN
NEWS 16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17	Dec 17	TOXCENTER enhanced with additional content
NEWS 18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 20	Feb 13	CANCERLIT is no longer being updated
NEWS 21	Feb 24	METADEX enhancements
NEWS 22	Feb 24	PCTGEN now available on STN
NEWS 23	Feb 24	TEMA now available on STN
NEWS 24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 25	Feb 26	PCTFULL now contains images
NEWS 26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27	Mar 19	APOLLIT offering free connect time in April 2003
NEWS 28	Mar 20	EVENTLINE will be removed from STN
NEWS 29	Mar 24	PATDPAFULL now available on STN
NEWS 30	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 31	Apr 11	Display formats in DGENE enhanced
NEWS 32	Apr 14	MEDLINE Reload
NEWS 33	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 34	Apr 21	Indexing from 1947 to 1956 being added to records in CA/CAPLUS
NEWS 35	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX

NEWS EXPRESS	April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that

10/ 005,133

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:09:55 ON 25 APR 2003

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:10:03 ON 25 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 APR 2003 HIGHEST RN 505023-70-1
DICTIONARY FILE UPDATES: 24 APR 2003 HIGHEST RN 505023-70-1

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 10005133.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

10/ 005,133



G1 C,N

G2 H,Ak

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 15:10:25 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     98 TO ITERATE

100.0% PROCESSED      98 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         1367 TO     2553
PROJECTED ANSWERS:               0 TO        0

L2             0 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 15:10:32 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   1945 TO ITERATE

100.0% PROCESSED    1945 ITERATIONS                              30 ANSWERS
SEARCH TIME: 00.00.01

L3            30 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     148.15     148.36

FILE 'CAPLUS' ENTERED AT 15:10:39 ON 25 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```

10/ 005,133

FILE COVERS 1907 - 25 Apr 2003 VOL 138 ISS 18
FILE LAST UPDATED: 24 Apr 2003 (20030424/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 9 L3

=> d l4 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 9 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2003:150531 CAPLUS
DOCUMENT NUMBER: 138:187765
TITLE: Preparation of heteroarylpyrazoles as p38 kinase inhibitors
INVENTOR(S): Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce Zuowu; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Graneto, Matthew J.; Hanau, Cathleen E.; Hanson, Gunnar J.; Hartmann, Susan J.; Hepperle, Michael; Huang, He; Koszyk, Francis J.; Liao, Shuyuan; Metz, Suzanne; Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar N.; Selness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Talley, John Jeffrey; Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong; Khanna, Ish K.; Yu, Yi
PATENT ASSIGNEE(S): G. D. Searle & Company, USA
SOURCE: U.S., 415 pp., Cont.-in-part of U.S. Ser. No. 196,623.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6525059	B1	20030225	US 2000-513351	20000224
US 6514977	B1	20030204	US 1998-196623	19981120
WO 2000031063	A1	20000602	WO 1999-US26007	19991117

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1998-196623 A2 19981120
WO 1999-US26007 A1 19991117
US 1997-47570P P 19970522
US 1998-83670 A2 19980522
OTHER SOURCE(S): MARPAT 138:187765
GI



I



II

AB Title compds. [I; R1 = H, OH, NH2, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = (un)substituted piperidinyl; R3 = (un)substituted pyrimidinyl; R4 = (un)substituted Ph; and pharmaceutically acceptable salts or tautomers thereof] were prepd. by soln. phase and solid phase parallel array reactions of ketones with hydrazines. Thus, R3CH2COMe (R3 = 4-pyridinyl) was condensed with 3,4-F(MeO)C6H3CHO to give the butenone (80%), which was cyclocondensed with TsNHNH2 to afford the title compd. II (20.7%). The latter inhibited human p38 kinase activity in vitro with IC50 of 4.6 .mu.M and inhibited tumor necrosis factor .alpha. (TNF.alpha.) and interleukin 1.beta. (IL-1.beta.) release from human peripheral blood mononuclear cells following stimulation with lipopolysaccharide with IC50 of 0.5 .mu.M. Thus, I are useful for the treatment of inflammation, arthritis, asthma, and other disorders mediated by p38 kinase and TNF.alpha..

IT **216504-84-6P 216504-85-7P 216505-37-2P**
216505-48-5P 216505-49-6P 216507-06-1P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(p38 kinase inhibitor; prepn. of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)

RN 216504-84-6 CAPLUS
CN 2-Pyridinamine, 4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216504-85-7 CAPLUS
CN 2-Pyridinamine, 4-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216505-37-2 CAPLUS
CN 2-Pyridinamine, N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



RN 216505-48-5 CAPLUS
CN 2-Pyrimidinamine, 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



RN 216505-49-6 CAPLUS
CN 2-Pyrimidinamine, N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



10/ 005,133

RN 216507-06-1 CAPLUS
CN 1H-Pyrazole-1-ethanol, 5-(4-fluorophenyl)-4-[2-[[(4-fluorophenyl)methyl]amino]-4-pyridinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 75 THERE ARE 75 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2003:92403 CAPLUS
DOCUMENT NUMBER: 138:137307
TITLE: Preparation of heteroarylpyrazoles as p38 kinase inhibitors
INVENTOR(S): Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce Zuowu; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Graneto, Matthew J.; Hanau, Cathleen E.; Hanson, Gunnar J.; Hartmann, Susan J.; Hepperle, Michael; Huang, He; Koszyk, Francis J.; Liao, Shuyuan; Metz, Suzanne; Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar N.; Selness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Talley, John Jeffrey; Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong; Khanna, Ish K.; Yu, Yi
PATENT ASSIGNEE(S): G.D. Searle & Company, USA
SOURCE: U.S., 541 pp., Cont.-in-part of U.S. Ser. No. 83,670.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6514977	B1	20030204	US 1998-196623	19981120
WO 2000031063	A1	20000602	WO 1999-US26007	19991117
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1144403	A1	20011017	EP 1999-965756	19991117
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

10/ 005,133

BR 9915420	A	20020122	BR 1999-15420		19991117
EE 200100268	A	20021216	EE 2001-20010026819991117		
US 6525059	B1	20030225	US 2000-513351		20000224
NO 2001002456	A	20010719	NO 2001-2456		20010518
US 6423713	B1	20020723	US 2001-918481		20010731
PRIORITY APPLN. INFO.:			US 1997-47570P	P	19970522
			US 1998-83670	A2	19980522
			US 1998-196623	A	19981120
			WO 1999-US26007	W	19991117

OTHER SOURCE(S): MARPAT 138:137307

GI



I



II

AB Title compds. [I; R1 = H, OH, NH2, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = (un)substituted piperidinyl or piperazinyl; R3 = (un)substituted pyrimidinyl; R4 = (un)substituted Ph; and pharmaceutically acceptable salts or tautomers thereof] were prepd. by soln. phase and solid phase parallel array reactions of ketones with hydrazines. Thus, R3CH2COMe (R3 = 4-pyridinyl) was condensed with 3,4-F(MeO)C6H3CHO to give the butenone (80%), which was cyclocondensed with TsNHNH2 to afford the title compd. II (20.7%). The latter inhibited human p38 kinase activity in vitro with IC50 of 4.6 .mu.M and inhibited tumor necrosis factor .alpha. (TNF.alpha.) and interleukin 1.beta. (IL-1.beta.) release from human peripheral blood mononuclear cells following stimulation with lipopolysaccharide with IC50 of 0.5 .mu.M. Thus, I are useful for the treatment of inflammation, arthritis, asthma, and other disorders mediated by p38 kinase and TNF.alpha..

IT **216504-84-6P 216504-85-7P 216505-37-2P**
216505-48-5P 216505-49-6P 216507-06-1P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(p38 kinase inhibitor; prepn. of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)

RN 216504-84-6 CAPLUS

CN 2-Pyridinamine, 4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

10/ 005,133



RN 216504-85-7 CAPLUS
CN 2-Pyridinamine, 4-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216505-37-2 CAPLUS
CN 2-Pyridinamine, N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



RN 216505-48-5 CAPLUS
CN 2-Pyrimidinamine, 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)

10/ 005,133



RN 216505-49-6 CAPLUS
CN 2-Pyrimidinamine, N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)-(9CI) (CA INDEX NAME)



RN 216507-06-1 CAPLUS
CN 1H-Pyrazole-1-ethanol, 5-(4-fluorophenyl)-4-[2-[[(4-fluorophenyl)methyl]amino]-4-pyridinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 76 THERE ARE 76 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:888716 CAPLUS
DOCUMENT NUMBER: 137:384853
TITLE: Preparation of pyrazolyl pyridinamines and pyrimidinamines as inhibitors of Src and other protein kinases
INVENTOR(S): Moon, Young-Choon
PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

10/ 005,133

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092573	A2	20021121	WO 2002-US15606	20020516

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: WO 2002-US15606 20020516
OTHER SOURCE(S): MARPAT 137:384853
GI



I



II

AB Title compds. I [wherein G = XR or XAr; X = independently alkylidene wherein 1-2 non-adjacent methylene units are independently replaced by O, NR, S, CO, CONR, NRCO, NRCONR, SO, SO2, NRSO2, SO2NR, or NRSO2NR; A = N or CR; R = H or (un)substituted aliph. group; or NR2 = heterocyclyl; Ar = (un)substituted 5-6 membered monocyclic ring with 0-3 heteroatoms or 8-10 membered bicyclic ring with 0-4 heteroatoms; R1 = TnR or TnAr; n = 0-1; T = CO, CO2, COCO, COCH2CO, CONR, SO2, or SO2NR; R2 = H, Ar, or (un)substituted aliph. group; R3 = R or Ar; or pharmaceutically acceptable derivs. thereof] were prepd. as inhibitors of protein kinase, particularly inhibitors of Src mammalian protein kinase involved in cell proliferation, cell death and response to extracellular stimuli (no data). For example, 3-dimethylamino-1-[5-methyl-3-methylsulfanyl-1-(pyridin-2-yl)-1H-pyrazol-4-yl]propenone was coupled with N-(3-benzyloxyphenyl)guanidine in MeOH to give II (40%). I and compns. contg. I are useful in the treatment and prevention of various inflammatory, autoimmune, destructive bone, proliferative, infectious, neurodegenerative, allergic, and cardiac disorders and diseases (no data).

IT **475574-56-2P**, N-(3-(Benzyloxy)phenyl)-N-[4-[5-methyl-3-(2-(methylthio)ethyl)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine
475574-57-3P, N-(3-Phenoxyphenyl)-N-[4-[5-methyl-3-(2-(methylthio)ethyl)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine
475574-58-4P, N-(3-Chlorophenyl)-N-[4-[5-methyl-3-(2-(methylthio)ethyl)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine
475574-59-5P, N-(3-Methoxyphenyl)-N-[4-[5-methyl-3-(2-

(methylthio)ethyl)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine
475574-60-8P, N-(3-(Methoxycarbonyl)phenyl)-N-[4-[5-methyl-3-(2-(methylthio)ethyl)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Src protein kinase inhibitor; prepn. of pyrazolyl pyridinamines and pyrimidinamine inhibitors of protein kinases using condensation, cyclization, and substitution reactions)

RN 475574-56-2 CAPLUS
CN 2-Pyrimidinamine, 4-[5-methyl-3-[2-(methylthio)ethyl]-1-phenyl-1H-pyrazol-4-yl]-N-[3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 475574-57-3 CAPLUS
CN 2-Pyrimidinamine, 4-[5-methyl-3-[2-(methylthio)ethyl]-1-phenyl-1H-pyrazol-4-yl]-N-(3-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 475574-58-4 CAPLUS
CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-[5-methyl-3-[2-(methylthio)ethyl]-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

10/ 005,133



RN 475574-59-5 CAPLUS
CN 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-[5-methyl-3-[2-(methylthio)ethyl]-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 475574-60-8 CAPLUS
CN Benzoic acid, 3-[[4-[5-methyl-3-[2-(methylthio)ethyl]-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:591913 CAPLUS
DOCUMENT NUMBER: 137:150215
TITLE: Cdk4 and/or Cdk6 inhibitors with biaryl ureas and their salts as antitumor agents
INVENTOR(S): Hatayama, Satoshi; Hayashi, Kyoko; Honma, Mitsuki; Takahashi, Ikuko
PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan

10/ 005,133

SOURCE: Jpn. Kokai Tokkyo Koho, 194 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002220338	A2	20020809	JP 2001-18755	20010126

PRIORITY APPLN. INFO.: JP 2001-18755 20010126
OTHER SOURCE(S): MARPAT 137:150215
GI



I

AB This invention relates to the general structures (I; Ar = N-contg. hetero arom. ring, X, Z = C, etc.; Y = CO, etc.; R1-R5 = H, etc.) and their salts as Cdk4 and/or Cdk6 inhibitors. I have antiproliferative effects on cancer cells and are potential antitumor agents. Formulation examples of I capsules, tablets, and injections were given.

IT **322685-65-4**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Cdk4 and/or Cdk6 inhibitors with biaryl ureas and their salts as antitumor agents)

RN 322685-65-4 CAPLUS

CN Urea, N-[4-[1-(phenylmethyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



10/ 005,133

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:449675 CAPLUS
DOCUMENT NUMBER: 137:33311
TITLE: Preparation of pyrazolylpyridine- and -pyrimidineamines as JNK inhibitors
INVENTOR(S): Ledeboer, Mark; Salituro, Francesco; Moon, Young-Choon
PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046184	A1	20020613	WO 2001-US46383	20011205
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002028783	A5	20020618	AU 2002-28783	20011205
US 2002111353	A1	20020815	US 2001-5133	20011205

PRIORITY APPLN. INFO.: US 2000-251409P P 20001205
WO 2001-US46383 W 20011205

OTHER SOURCE(S): MARPAT 137:33311
GI

Applicant's prepared Pub.



I

AB Title compds. (I; R = H or alkyl; R1 = cycloalkyl, Ph, pyridyl, etc.; R2 = H, alkoxymethyl, heterocyclylmethyl, etc.; R3 = Ph, CH2Ph, etc.; Z1 = pyridine- or pyrimidine-4,2-diyl) were prepd. Thus, R4Z1CH(CHO)2 (R4 = MeS, Z1 = pyrimidine-2,4-diyl) was cyclocondensed with H2NNHC6H3F2-2,4 and the S-oxidized product aminated by cyclohexylamine to give I (R = R2 = H, R1 = cyclohexyl, R3 = C6H3F2-2,4). Data for biol. activity of I were given.

IT **434283-94-0P 434283-95-1P 434283-96-2P 434283-97-3P 434283-98-4P 434283-99-5P 434284-00-1P 434284-01-2P 434284-02-3P 434284-03-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrazolylpyridine- and -pyrimidineamines as JNK inhibitors)

RN 434283-94-0 CAPLUS
CN 2-Pyrimidinamine, N-cyclohexyl-4-[1-(2,4-difluorophenyl)-1H-pyrazol-4-yl]-

10/ 005,133

(9CI) (CA INDEX NAME)



RN 434283-95-1 CAPLUS
CN 2-Pyrimidinamine, 4-(3-methyl-1-phenyl-1H-pyrazol-4-yl)-N-phenyl- (9CI) (CA INDEX NAME)



RN 434283-96-2 CAPLUS
CN Benzenesulfonamide, 4-[[4-(5-methyl-1-phenyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434283-97-3 CAPLUS
CN 2-Pyrimidinamine, N-cyclohexyl-4-[1-(phenylmethyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 434283-98-4 CAPLUS
CN 2-Pyrimidinamine, N-cyclohexyl-4-(1-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



RN 434283-99-5 CAPLUS
CN 2-Pyrimidinamine, N-cyclohexyl-4-[1-(4-methoxyphenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 434284-00-1 CAPLUS
CN 2-Pyrimidinamine, N-cyclohexyl-4-[1-(2,5-dichlorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

10/ 005,133



RN 434284-01-2 CAPLUS
CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-(5-methyl-1-phenyl-1H-pyrazol-4-yl)-
(9CI) (CA INDEX NAME)



RN 434284-02-3 CAPLUS
CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(5-methyl-1-phenyl-1H-pyrazol-4-yl)-
(9CI) (CA INDEX NAME)



RN 434284-03-4 CAPLUS
CN 2-Pyrimidinamine, 4-(5-methyl-1-phenyl-1H-pyrazol-4-yl)-N-(4-nitrophenyl)-
(9CI) (CA INDEX NAME)

10/ 005,133



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:78363 CAPLUS
DOCUMENT NUMBER: 134:147614
TITLE: Preparation of N,N'-biarylurea derivatives as inhibitors of cyclin-dependent kinases (Cdk4 and Cdk6)
INVENTOR(S): Hayama, Takashi; Hayashi, Kyoko; Honma, Mitsutaka; Takahashi, Ikuko
PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 460 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007411	A1	20010201	WO 2000-JP4991	20000726
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2001106673	A2	20010417	JP 2000-274175	20000726
EP 1199306	A1	20020424	EP 2000-949909	20000726
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRIORITY APPLN. INFO.: JP 1999-211384 A 19990726
WO 2000-JP4991 W 20000726
OTHER SOURCE(S): MARPAT 134:147614
GI



I



II

AB N-(hetero)aryl-N'-heterocyclylurea derivs. represented by general formula (I) [wherein Ar represents a nitrogenous heterocyclic arom. group such as (un)substituted pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, pyrrolyl, imidazolyl, indolyl, isoindolyl, quinolyl, isoquinolyl, benzothiazolyl, or benzoxazolyl; X and Z each represents C or N or together with R1 or R2 and/or R3 represent CH or N; Y represents CO, SO, or SO2; R1 represents hydrogen, (un)substituted lower alkyl, Y3-W2-Y4-R5, etc.; wherein R5 = H, (un)substituted lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, aryl, imidazolyl, isoxazolyl, isoquinolyl, isoindolyl, indazolyl, indolyl, indolidinyl, isothiazolyl, ethylenedioxyphenyl, oxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, quinoxalinyl, quinolyl, etc.; W2 = ingle bond, O, S, SO, SO2, N-(un)substituted NH, SO2NH, NHSO2NH, NHSO2, CONH, NHCO, NHCONH, NHCO2, etc.; Y3, Y4 = single bond, linear or branched lower alkylene; R2 and R3 each represents hydrogen, lower alkyl or alkoxy, or Y3-W2-Y4-R5 (Y3, W2, Y4, R5 = same as above), or one of R2 and R3 together with R1 and X forms cyclohexane, cyclopentane, piperidine, 3,4,5,6-tetrahydro-1,3-oxazine, tetrahydrothiopyran, pyrrolidine, tetrahydrothiofuran, oxazolidine ring, etc.; R4 and R5 represent H, halo, OH, amino, or Y3-W2-Y4-R5 (Y3, W2, Y4, R5 = same as above)] or salts thereof are prepd. The compds. (e.g. II) have a remarkable proliferation-inhibitory effect on tumor cells. A Cdk4 and/or Cdk6 inhibitor for use in the therapy of malignant tumor can hence be provided. II showed IC50 of 0.061 and 0.019 .mu.M against cyclin-D1-Cdk4 and cyclin-D2-Cdk4, resp., vs. 0.36 and 0.056 .mu.M, resp., for (.+-.)-flavopiridol, and inhibited the proliferation of HCT116 and MKN-1 cells with IC50 of 0.013 and 0.10 .mu.M, resp., vs. 0.15 and 0.87 .mu.M, resp., for (.+-.)-flavopiridol. Pharmaceutical formulations contg. I were prepd.

IT **322685-65-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-(hetero)aryl-N'-heterocyclylurea derivs. as inhibitors of cyclin-dependent kinases (Cdk4 and Cdk6) and antitumor agents)

RN 322685-65-4 CAPLUS

CN Urea, N-[4-[1-(phenylmethyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:368337 CAPLUS
DOCUMENT NUMBER: 133:4656
TITLE: Preparation of heteroarylpyrazoles as p38 kinase inhibitors
INVENTOR(S): Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce Z.; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Graneto, Matthew J.; Hanau, Cathleen E.; Hanson, Gunnar J.; Hartmann, Susan J.; Hepperle, Michael; Huang, He; Khanna, Ish K.; Koszyk, Francis J.; Liao, Shuyuan; Metz, Suzanne; Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar N.; Selness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Talley, John Jeffrey; Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong; Yu, Yi
PATENT ASSIGNEE(S): G.D. Searle & Co., USA
SOURCE: PCT Int. Appl., 1210 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000031063	A1	20000602	WO 1999-US26007	19991117
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6514977	B1	20030204	US 1998-196623	19981120
EP 1144403	A1	20011017	EP 1999-965756	19991117
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO

BR 9915420	A	20020122	BR 1999-15420	19991117
EE 200100268	A	20021216	EE 2001-200100268	19991117
US 6525059	B1	20030225	US 2000-513351	20000224
NO 2001002456	A	20010719	NO 2001-2456	20010518

PRIORITY APPLN. INFO.:

US 1998-196623	A	19981120
US 1997-47570P	P	19970522
US 1998-83670	A2	19980522
WO 1999-US26007	W	19991117

OTHER SOURCE(S): MARPAT 133:4656

GI



I



II

AB Title compds. [I; R1 = H, OH, NH2, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = H, halo, alkyl, alkoxy, (un)substituted piperidinyl, etc.; R3 = pyridyl, pyrimidinyl, quinolyl, etc.; R4 = H, alkyl, heterocyclyl, aryl, etc.] were prepd. by reaction of ketones with hydrazines. Thus, R3CH2COMe (R3 = 4-pyridinyl) was condensed with 3,4-F(MeO)C6H3CHO and the product cyclocondensed with TsNHNH2 to give title compd. II. Data for biol. activity of I were given.

IT **216504-84-6P 216504-85-7P 216505-37-2P**
216505-48-5P 216505-49-6P 216507-06-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)

RN 216504-84-6 CAPLUS

CN 2-Pyridinamine, 4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216504-85-7 CAPLUS

CN 2-Pyridinamine, 4-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

10/ 005,133



RN 216505-37-2 CAPLUS
CN 2-Pyridinamine, N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



RN 216505-48-5 CAPLUS
CN 2-Pyrimidinamine, 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



RN 216505-49-6 CAPLUS
CN 2-Pyrimidinamine, N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



10/ 005,133

RN 216507-06-1 CAPLUS
CN 1H-Pyrazole-1-ethanol, 5-(4-fluorophenyl)-4-[2-[[(4-fluorophenyl)methyl]amino]-4-pyridinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:700930 CAPLUS
DOCUMENT NUMBER: 132:151766
TITLE: Synthesis and antimicrobial activity of 4-(4-pyrazolyl)-2-aminopyrimidines
AUTHOR(S): Singh, Shiv P.; Batra, Hitesh; Naithani, Rajesh; Prakash, Om
CORPORATE SOURCE: Department of Chemistry, Kurukshetra University, Kurukshetra, 136 119, India
SOURCE: Indian Journal of Heterocyclic Chemistry (1999), 9(1), 73-74
CODEN: IJCHEI; ISSN: 0971-1627
PUBLISHER: Prof. R. S. Varma
DOCUMENT TYPE: Journal
LANGUAGE: English
AB 1-(Pyrazol-4-yl)-1,3 butanediones on condensation with guanidine carbonate give 4-(4-pyrazolyl)-2-aminopyrimidines in good yields. A few compds. show moderate level of antimicrobial activity.
IT **257625-23-3P 257625-24-4P 257625-25-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and antimicrobial activity of [hydroxy(methyl)pyrazolyl]pyrimidinamines)
RN 257625-23-3 CAPLUS
CN 1H-Pyrazol-5-ol, 4-(2-amino-6-methyl-4-pyrimidinyl)-3-methyl-1-phenyl- (9CI) (CA INDEX NAME)



R² - not a hydroxy

10/ 005,133

RN 257625-24-4 CAPLUS
CN 1H-Pyrazol-5-ol, 4-(2-amino-6-methyl-4-pyrimidinyl)-1-(4-chlorophenyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 257625-25-5 CAPLUS
CN 1H-Pyrazol-5-ol, 4-(2-amino-6-methyl-4-pyrimidinyl)-3-methyl-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)



IT **257625-26-6P 257625-27-7P 257625-28-8P**
257625-29-9P 257625-30-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 257625-26-6 CAPLUS
CN 1H-Pyrazol-5-ol, 4-(2-amino-6-methyl-4-pyrimidinyl)-1-(2-benzothiazolyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 257625-27-7 CAPLUS
CN 1H-Pyrazol-5-ol, 4-(2-amino-6-methyl-4-pyrimidinyl)-3-methyl-1-(4-methyl-2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 257625-28-8 CAPLUS
CN 1H-Pyrazol-5-ol, 4-(2-amino-6-methyl-4-pyrimidinyl)-3-methyl-1-(4-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 257625-29-9 CAPLUS
CN 1H-Pyrazol-5-ol, 4-(2-amino-6-methyl-4-pyrimidinyl)-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 257625-30-2 CAPLUS
CN 1H-Pyrazol-5-ol, 4-(2-amino-6-methyl-4-pyrimidinyl)-3-methyl-1-(6-methyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

10/ 005,133



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:789144 CAPLUS
DOCUMENT NUMBER: 130:38377
TITLE: Preparation of heteroarylpyrazoles as p38 kinase inhibitors
INVENTOR(S): Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce Zuowu; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Hanson, Gunnar J.; Koszyk, Francis J.; Liao, Shuyuan; Partis, Richard A.; Rao, Shashidhar N.; Selness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Weier, Richard M.; Xu, Xiangdong
PATENT ASSIGNEE(S): G.D. Searle and Co., USA; et al.
SOURCE: PCT Int. Appl., 828 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9852940	A1	19981126	WO 1998-US10436	19980522
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9875883	A1	19981211	AU 1998-75883	19980522
AU 754830	B2	20021128		
ZA 9804358	A	19990524	ZA 1998-4358	19980522
EP 1000055	A1	20000517	EP 1998-923642	19980522
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EE 9900527	A	20000615	EE 1999-527	19980522
BR 9809147	A	20000801	BR 1998-9147	19980522
JP 2002508754	T2	20020319	JP 1998-550650	19980522
NZ 501112	A	20021025	NZ 1998-501112	19980522
NO 9905695	A	20000121	NO 1999-5695	19991119
MX 9910759	A	20000531	MX 1999-10759	19991122

PRIORITY APPLN. INFO.: US 1997-47570P P 19970522
WO 1998-US10436 W 19980522
OTHER SOURCE(S): MARPAT 130:38377
GI

10/ 005,133



I



II

AB Title compds. [I; R1 = H, NH2, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = H, halo, alkyl, alkoxy, etc.; R3 = pyridyl, pyrimidinyl, quinolyl, etc.; R4 = H, alkyl, heterocyclyl, aryl, etc.] were prepd. Thus, R3CH2COMe (R3 = 4-pyridinyl) was condensed with 3,4-F(MeO)C6H3CHO and the product cyclocondensed with TsNHNH2 to give title compd. II. Data for biol. activity of I were given.

IT **216504-84-6P 216504-85-7P 216505-37-2P**
216505-48-5P 216505-49-6P 216507-06-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heteroarylpyrazoles as p38 kinase inhibitors)

RN 216504-84-6 CAPLUS

CN 2-Pyridinamine, 4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216504-85-7 CAPLUS

CN 2-Pyridinamine, 4-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216505-37-2 CAPLUS

10/ 005,133

CN 2-Pyridinamine, N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



RN 216505-48-5 CAPLUS
CN 2-Pyrimidinamine, 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



RN 216505-49-6 CAPLUS
CN 2-Pyrimidinamine, N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



RN 216507-06-1 CAPLUS
CN 1H-Pyrazole-1-ethanol, 5-(4-fluorophenyl)-4-[2-[[(4-fluorophenyl)methyl]amino]-4-pyridinyl]- (9CI) (CA INDEX NAME)

10/ 005,133



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:09:55 ON 25 APR 2003)

FILE 'REGISTRY' ENTERED AT 15:10:03 ON 25 APR 2003
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 30 S L1 FUL

FILE 'CAPLUS' ENTERED AT 15:10:39 ON 25 APR 2003
L4 9 S L3

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	41.24	189.60
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.86	-5.86

STN INTERNATIONAL LOGOFF AT 15:11:30 ON 25 APR 2003